ACBI1 manufacturers
- ACBI1
-
- $200.00 / 100MG
-
2024-11-19
- CAS:2375564-55-7
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
- ACBI-1
-
- $0.00 / 100MG
-
2024-11-19
- CAS:2375564-55-7
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
- ACBI1
-
- $98.00 / 1mg
-
2024-11-18
- CAS:2375564-55-7
- Min. Order:
- Purity: 98.15%
- Supply Ability: 10g
|
Product Name: | ACBI1 | Synonyms: | ACBI1;PROTACs,anti-proliferative,ACBI 1,Epigenetic Reader Domain,ACBI1,Inhibitor,Apoptosis,inhibit,ACBI-1;N-[(1-Fluorocyclopropyl)carbonyl]-3-methyl-L-valyl-(4R)-N-[2-{2-[4-({4-[3-amino-6-(2-hydroxyphenyl)-4-pyridazinyl]-1-piperazinyl}methyl)phenoxy]ethoxy}-4-(4-methyl-1,3-thiazol-5-yl)benzyl]-4-hydroxy-L-prolinamide;(2S,4R)-N-(2-(2-(4-((4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)phenoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide | CAS: | 2375564-55-7 | MF: | C49H58FN9O7S | MW: | 936.12 | EINECS: | | Product Categories: | | Mol File: | 2375564-55-7.mol | |
| ACBI1 Chemical Properties |
Boiling point | 1144.1±65.0 °C(Predicted) | density | 1.41±0.1 g/cm3(Predicted) | pka | 6.22±0.30(Predicted) | form | Solid | color | White to yellow | InChIKey | IVARZBJJMMUJHI-SSIILETPNA-N | SMILES | NC1N=NC(C2C=CC=CC=2O)=CC=1N1CCN(CC2C=CC(OCCOC3C=C(C4SC=NC=4C)C=CC=3CNC([C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)(C)C)NC(C3(CC3)F)=O)=O)=CC=2)CC1 |&1:42,44,50,r| |
| ACBI1 Usage And Synthesis |
Definition | ACBI1 is a potent and cooperative SMARCA2, SMARCA4 and PBRM1 degrader with DC50s of 6, 11 and 32 nM, respectively. ACBI1 is a PROTAC degrader. ACBI1 shows anti-proliferative activity and can induce apoptosis. It induced anti-proliferative effects and cell death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells and acute myeloid leukemia cells dependent on SMARCA4 ATPase activity[1]. | References | [1] William Farnaby. “BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.” Nature chemical biology 15 7 (2019): 672–680. [2] M. Koegl. “Abstract 3849: Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer.” Experimental and Molecular Therapeutics 36 1 (2019). |
| ACBI1 Preparation Products And Raw materials |
|